On July 26th, CICC research reports pointed out that the acquisition of Juyiyuan consolidated the overall competitiveness of molecular imaging sector of United Imaging Healthcare (688271.SH), and the target price of 160 yuan was temporarily maintained unchanged, and the 'outperform industry' rating was maintained. Juyiyuan is mainly engaged in the research and development, production, and sales of cyclotrons, and its main products include cyclotrons with different energy levels such as 7MeV, 11MeV, and 20MeV. Medical cyclotrons are mainly used for the preparation of PET, PET/CT, and PET/MR related positron-emitting isotopes in the field of nuclear medicine. It is one of the core equipment for nuclear medicine diagnosis and treatment, and related equipment has advantages in the treatment of diseases such as malignant tumors and cardiovascular and cerebrovascular diseases. According to the company's announcement, Juyiyuan's revenue in 2023 was 46.83 million yuan, and the net loss was 9.96 million yuan. On the other hand, Juyiyuan made performance commitments in this transaction: 1) The revenue in 2023 will not be less than 80 million yuan, or the cumulative revenue from 2023 to 2025 will be 250 million yuan; and 2) In 2024, Juyiyuan's 20MeV medical cyclotron product will obtain at least 3 sales orders. The bank believes that through this participation in the investment in Juyiyuan, United Imaging Healthcare is expected to further enhance the company's overall solution capabilities in the molecular imaging sector in the future, and continue to consolidate the company's leading position in the molecular imaging sector.